Review



cxcl5 monoclonal antibodies  (R&D Systems)


Bioz Verified Symbol R&D Systems is a verified supplier
Bioz Manufacturer Symbol R&D Systems manufactures this product  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
    • 94
      Buy from Supplier

    Structured Review

    R&D Systems cxcl5 monoclonal antibodies
    Cxcl5 Monoclonal Antibodies, supplied by R&D Systems, used in various techniques. Bioz Stars score: 94/100, based on 15 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/monoclonal+antibody+anti+cxcl5/Human+CXCL5%2FENA-78+Antibody/pm39326648-162-0-7
    Average 94 stars, based on 15 article reviews
    cxcl5 monoclonal antibodies - by Bioz Stars, 2026-10
    94/100 stars

    Images

    Related Articles

    other:

    Article Title: Disrupted Expression of CXCL5 in Colorectal Cancer Is Associated with Rapid Tumor Formation in Rats and Poor Prognosis in Patients
    Article Snippet: The primary antibodies used were as follows: the monoclonal antibody anti-CXCL5 (clone MAB254; R&D Systems), the monoclonal antibody anti-CD4 (clone 1F6; Novocastra), the monoclonal antibody anti-CD8 (clone 4B11; Novocastra), and rabbit anti-human laminin polyclonal Ab (Sigma-Aldrich).



    Similar Products

    cxcl5 monoclonal antibodies  (R&D Systems)
    94
    R&D Systems cxcl5 monoclonal antibodies
    Cxcl5 Monoclonal Antibodies, supplied by R&D Systems, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/monoclonal+antibody+anti+cxcl5/Human+CXCL5%2FENA-78+Antibody/pm39326648-162-0-7
    Average 94 stars, based on 1 article reviews
    cxcl5 monoclonal antibodies - by Bioz Stars, 2026-10
    94/100 stars
    		  Buy from Supplier
    cxcl5 monoclonal antibody  (R&D Systems)
    94
    R&D Systems cxcl5 monoclonal antibody
    Fig. 2 Treatment with <t>CXCL5</t> neutralizing antibody upregulated VEGF/SDF-1 expression and promoted angiogenesis in late-EPCs from non-DM subjects and HAECs under the HG conditions. The network formation and migration abilities were improved after the administration of CXCL5 mAb in EPCs from non-DM subjects (n = 3; A, B). Western blotting and statistical analyses of VEGF and SDF-1 in EPCs from non-DM subjects (n = 3; C). The network formation and migration abilities were improved after the administration of CXCL5 mAb in HAECs (n = 3; D, E). Western blotting and statistical analyses of VEGF and SDF-1 in HAECs (n = 3; F). CXCL5 C-X-C motif chemokine ligand 5, EPC endothelial progenitor cell, HG high glucose, HAEC human aortic endothelial cell, mAb,monoclonal antibody, SDF-1 stromal cell-derived factor 1, VEGF vascular endothelial growth factor. N represents the number of independent experiments on different days and in different experimental runs. The Mann–Whitney U test was used to determine statistically significant differences. *p < 0.05, **p < 0.01
    Cxcl5 Monoclonal Antibody, supplied by R&D Systems, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/monoclonal+antibody+anti+cxcl5/Human+CXCL5%2FENA-78+Antibody/pm37420254-68-5-13
    Average 94 stars, based on 1 article reviews
    cxcl5 monoclonal antibody - by Bioz Stars, 2026-10
    94/100 stars
    		  Buy from Supplier
    cxcl5 monoclonal antibody  (Danaher Inc)
    86
    Danaher Inc cxcl5 monoclonal antibody
    Fig. 2 Treatment with <t>CXCL5</t> neutralizing antibody upregulated VEGF/SDF-1 expression and promoted angiogenesis in late-EPCs from non-DM subjects and HAECs under the HG conditions. The network formation and migration abilities were improved after the administration of CXCL5 mAb in EPCs from non-DM subjects (n = 3; A, B). Western blotting and statistical analyses of VEGF and SDF-1 in EPCs from non-DM subjects (n = 3; C). The network formation and migration abilities were improved after the administration of CXCL5 mAb in HAECs (n = 3; D, E). Western blotting and statistical analyses of VEGF and SDF-1 in HAECs (n = 3; F). CXCL5 C-X-C motif chemokine ligand 5, EPC endothelial progenitor cell, HG high glucose, HAEC human aortic endothelial cell, mAb,monoclonal antibody, SDF-1 stromal cell-derived factor 1, VEGF vascular endothelial growth factor. N represents the number of independent experiments on different days and in different experimental runs. The Mann–Whitney U test was used to determine statistically significant differences. *p < 0.05, **p < 0.01
    Cxcl5 Monoclonal Antibody, supplied by Danaher Inc, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/monoclonal+antibody+anti+cxcl5/pm37201403-99-22-27
    Average 86 stars, based on 1 article reviews
    cxcl5 monoclonal antibody - by Bioz Stars, 2026-10
    86/100 stars
    		  Buy from Supplier
    anti cxcl5 monoclonal antibody mab  (R&D Systems)
    94
    R&D Systems anti cxcl5 monoclonal antibody mab
    Fig. 2 Treatment with <t>CXCL5</t> neutralizing antibody upregulated VEGF/SDF-1 expression and promoted angiogenesis in late-EPCs from non-DM subjects and HAECs under the HG conditions. The network formation and migration abilities were improved after the administration of CXCL5 mAb in EPCs from non-DM subjects (n = 3; A, B). Western blotting and statistical analyses of VEGF and SDF-1 in EPCs from non-DM subjects (n = 3; C). The network formation and migration abilities were improved after the administration of CXCL5 mAb in HAECs (n = 3; D, E). Western blotting and statistical analyses of VEGF and SDF-1 in HAECs (n = 3; F). CXCL5 C-X-C motif chemokine ligand 5, EPC endothelial progenitor cell, HG high glucose, HAEC human aortic endothelial cell, mAb,monoclonal antibody, SDF-1 stromal cell-derived factor 1, VEGF vascular endothelial growth factor. N represents the number of independent experiments on different days and in different experimental runs. The Mann–Whitney U test was used to determine statistically significant differences. *p < 0.05, **p < 0.01
    Anti Cxcl5 Monoclonal Antibody Mab, supplied by R&D Systems, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/monoclonal+antibody+anti+cxcl5/Mouse+LIX+Antibody/pm34653642-61-36-41
    Average 94 stars, based on 1 article reviews
    anti cxcl5 monoclonal antibody mab - by Bioz Stars, 2026-10
    94/100 stars
    		  Buy from Supplier
    anti human cxcl5 monoclonal antibody  (R&D Systems)
    94
    R&D Systems anti human cxcl5 monoclonal antibody
    Figure 1. Venn diagram of DE chemokines or DE chemokine receptors. <t>CXCL5</t> was identified in all datasets and was selected for further analysis. DE, differentially expressed.
    Anti Human Cxcl5 Monoclonal Antibody, supplied by R&D Systems, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/monoclonal+antibody+anti+cxcl5/Human+CXCL5%2FENA-78+Antibody/pm32994820-68-1-10
    Average 94 stars, based on 1 article reviews
    anti human cxcl5 monoclonal antibody - by Bioz Stars, 2026-10
    94/100 stars
    		  Buy from Supplier
    rat anti mouse cxcl5 monoclonal  (R&D Systems)
    93
    R&D Systems rat anti mouse cxcl5 monoclonal
    Figure 1. Venn diagram of DE chemokines or DE chemokine receptors. <t>CXCL5</t> was identified in all datasets and was selected for further analysis. DE, differentially expressed.
    Rat Anti Mouse Cxcl5 Monoclonal, supplied by R&D Systems, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/monoclonal+antibody+anti+cxcl5/Rat+Anti-Mouse+IgG2B+PE-conjugated+Antibody/pmc06507428-591-5-11
    Average 93 stars, based on 1 article reviews
    rat anti mouse cxcl5 monoclonal - by Bioz Stars, 2026-10
    93/100 stars
    		  Buy from Supplier

    Image Search Results


    Fig. 2 Treatment with CXCL5 neutralizing antibody upregulated VEGF/SDF-1 expression and promoted angiogenesis in late-EPCs from non-DM subjects and HAECs under the HG conditions. The network formation and migration abilities were improved after the administration of CXCL5 mAb in EPCs from non-DM subjects (n = 3; A, B). Western blotting and statistical analyses of VEGF and SDF-1 in EPCs from non-DM subjects (n = 3; C). The network formation and migration abilities were improved after the administration of CXCL5 mAb in HAECs (n = 3; D, E). Western blotting and statistical analyses of VEGF and SDF-1 in HAECs (n = 3; F). CXCL5 C-X-C motif chemokine ligand 5, EPC endothelial progenitor cell, HG high glucose, HAEC human aortic endothelial cell, mAb,monoclonal antibody, SDF-1 stromal cell-derived factor 1, VEGF vascular endothelial growth factor. N represents the number of independent experiments on different days and in different experimental runs. The Mann–Whitney U test was used to determine statistically significant differences. *p < 0.05, **p < 0.01

    Journal: Cardiovascular diabetology

    Article Title: CXCL5 suppression recovers neovascularization and accelerates wound healing in diabetes mellitus.

    doi: 10.1186/s12933-023-01900-w

    Figure Lengend Snippet: Fig. 2 Treatment with CXCL5 neutralizing antibody upregulated VEGF/SDF-1 expression and promoted angiogenesis in late-EPCs from non-DM subjects and HAECs under the HG conditions. The network formation and migration abilities were improved after the administration of CXCL5 mAb in EPCs from non-DM subjects (n = 3; A, B). Western blotting and statistical analyses of VEGF and SDF-1 in EPCs from non-DM subjects (n = 3; C). The network formation and migration abilities were improved after the administration of CXCL5 mAb in HAECs (n = 3; D, E). Western blotting and statistical analyses of VEGF and SDF-1 in HAECs (n = 3; F). CXCL5 C-X-C motif chemokine ligand 5, EPC endothelial progenitor cell, HG high glucose, HAEC human aortic endothelial cell, mAb,monoclonal antibody, SDF-1 stromal cell-derived factor 1, VEGF vascular endothelial growth factor. N represents the number of independent experiments on different days and in different experimental runs. The Mann–Whitney U test was used to determine statistically significant differences. *p < 0.05, **p < 0.01

    Article Snippet: Some cells were treated with CXCL5 monoclonal antibody (1 or 10 μg/ mL; R&D Systems, MAB-254, Minneapolis, MN, USA) or recombinant human CXCL5 protein (1 or 10 ng/mL; R&D Systems, 254-XB, Minneapolis, MN, USA).

    Techniques: Expressing, Migration, Western Blot, Derivative Assay, MANN-WHITNEY

    Fig. 7 Summary of beneficial effects of CXCL5 suppression in diabetic vasculopathy. CXCL5 Chemokine C-X-C motif ligand 5, CXCR2 Chemokine C-X-C motif receptor 2, EPC endothelial progenitor cell, ERK extracellular signal-regulated kinase, DM diabetes mellitus, IL interleukin, SDF-1 stromal cell-derived factor 1, TNF-α tumor necrosis factor-α, VEGF vascular endothelial growth factor

    Journal: Cardiovascular diabetology

    Article Title: CXCL5 suppression recovers neovascularization and accelerates wound healing in diabetes mellitus.

    doi: 10.1186/s12933-023-01900-w

    Figure Lengend Snippet: Fig. 7 Summary of beneficial effects of CXCL5 suppression in diabetic vasculopathy. CXCL5 Chemokine C-X-C motif ligand 5, CXCR2 Chemokine C-X-C motif receptor 2, EPC endothelial progenitor cell, ERK extracellular signal-regulated kinase, DM diabetes mellitus, IL interleukin, SDF-1 stromal cell-derived factor 1, TNF-α tumor necrosis factor-α, VEGF vascular endothelial growth factor

    Article Snippet: Some cells were treated with CXCL5 monoclonal antibody (1 or 10 μg/ mL; R&D Systems, MAB-254, Minneapolis, MN, USA) or recombinant human CXCL5 protein (1 or 10 ng/mL; R&D Systems, 254-XB, Minneapolis, MN, USA).

    Techniques: Derivative Assay

    Figure 1. Venn diagram of DE chemokines or DE chemokine receptors. CXCL5 was identified in all datasets and was selected for further analysis. DE, differentially expressed.

    Journal: Oncology letters

    Article Title: CXCL5 expression in tumor tissues is associated with poor prognosis in patients with pancreatic cancer.

    doi: 10.3892/ol.2020.12120

    Figure Lengend Snippet: Figure 1. Venn diagram of DE chemokines or DE chemokine receptors. CXCL5 was identified in all datasets and was selected for further analysis. DE, differentially expressed.

    Article Snippet: An anti‐human CXCL5 monoclonal antibody (1:50; cat. no. MAB 254‐100; R&D Systems) was used for analysis.

    Techniques:

    Figure 3. Expression of CXCL5 in pancreatic cancer. (A) Statistical compar ison of CXCL5 expression levels (H‑SCORE) in pancreatic cancer tumor tissues and adjacent peritumoral normal tissues. (B) CXCL5 was highly expressed in pancreatic cancer tumor tissues. (C) Low expression of CXCL5 in adjacent peritumoral normal tissues (magnification, x200). H‑SCORE, histochemistry score.

    Journal: Oncology letters

    Article Title: CXCL5 expression in tumor tissues is associated with poor prognosis in patients with pancreatic cancer.

    doi: 10.3892/ol.2020.12120

    Figure Lengend Snippet: Figure 3. Expression of CXCL5 in pancreatic cancer. (A) Statistical compar ison of CXCL5 expression levels (H‑SCORE) in pancreatic cancer tumor tissues and adjacent peritumoral normal tissues. (B) CXCL5 was highly expressed in pancreatic cancer tumor tissues. (C) Low expression of CXCL5 in adjacent peritumoral normal tissues (magnification, x200). H‑SCORE, histochemistry score.

    Article Snippet: An anti‐human CXCL5 monoclonal antibody (1:50; cat. no. MAB 254‐100; R&D Systems) was used for analysis.

    Techniques: Expressing

    Figure 4. Kaplan‑Meier survival curve according to CXCL5 expression levels in cancer tissues of patients with pancreatic cancer.

    Journal: Oncology letters

    Article Title: CXCL5 expression in tumor tissues is associated with poor prognosis in patients with pancreatic cancer.

    doi: 10.3892/ol.2020.12120

    Figure Lengend Snippet: Figure 4. Kaplan‑Meier survival curve according to CXCL5 expression levels in cancer tissues of patients with pancreatic cancer.

    Article Snippet: An anti‐human CXCL5 monoclonal antibody (1:50; cat. no. MAB 254‐100; R&D Systems) was used for analysis.

    Techniques: Expressing